MNKD Q3 2024 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$70M+36.7% YoY

Gross Profit

$52M74.3% margin

Operating Income

$13M18.2% margin

Net Income

$12M16.5% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$8M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$464M

Total Liabilities

$674M

Stockholders' Equity

-$210M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$51M	+36.7%
Gross Profit	$52M	$37M	+40.7%
Operating Income	$13M	$5M	+150.3%
Net Income	$12M	$2M	+571.1%

Revenue Segments

Royalty

$27M39%

License And Service

$23M33%

Product

$20M28%